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Effects of GPC1 antisense expression on GPC1 protein levels. (A) 
Effects of enzymatic treatment on immunoblotting. Sham-transfect-
ed cells and GPC1 antisense–expressing cells (clone GAS6) were 
incubated in the absence or presence of the indicated enzymes and 
subjected to immunoblotting using affinity-purified rabbit anti-GPC1 
antibody as reported in Methods. (B) Total cell lysates from sham-
transfected and from both antisense-expressing clones as well as the 
corresponding conditioned media were incubated with heparitinase 
and chondroitinase ABC and subjected to immunoblotting as described 
above. Membranes from cell lysates were reprobed with an anti-ERK2 
antibody to confirm equivalent loading of lanes. Each panel is repre-
sentative of 2 distinct experiments.
Figure 2
Cell growth assays. (A) Effects of GPC1 levels on basal 
anchorage-independent growth. Sham-transfected PANC-1 
cells and GPC1 antisense–expressing clones were seeded 
in 6-well plates (3,000/well) in complete medium contain-
ing 0.3% agar. After 14 days, colonies having more than 
20 cells were counted. Data indicate the mean ± SEM of 
triplicate determinations from 3 experiments. #P < 0.01 
compared with sham-transfected cells. (B) Effects of GPC1 
levels on growth factor–stimulated anchorage-independent 
growth. Sham-transfected (filled symbols) and GPC1 anti-
sense mRNA–expressing PANC-1 cells (open symbols) 
were seeded in 6-well plates (3,000/well) in serum-free 
medium containing 0.3% agar. Serum-free medium contain-
ing 1 nM HB-EGF, FGF2, EGF, or IGF-1 was added every 
4 days. After 14 days, colonies having more than 20 cells 
were counted. Data are expressed as percentage change 
from the respective controls (mean ± SEM) of 3 determi-
nations per experiment from 3 separate experiments. 
 *P < 0.05 and **P < 0.03 compared with control.
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Effects of GPC1 levels on tumor growth. (A) Representative tumors. 
GAS6 cells consistently formed smaller tumors than sham-transfected 
cells. The mice bearing GAS tumors appeared healthy. By contrast, 
the mice bearing tumors from sham-transfected cells had to be termi-
nated due to their cachectic appearance, tumor size, and tendency of 
the tumors to develop surface ulcerations. (B) Tumor growth curves. 
Exponentially growing (2 × 106) sham-transfected PANC-1 cells (filled 
diamonds) and GAS7 (open triangles) and GAS6 (open squares) cells 
were injected subcutaneously in athymic mice, and tumor growth was 
measured weekly. Tumor volume was determined by the equation: vol-
ume = (l × h × w) × π /4, where l is length, h is height, and w is width of 
the tumor. Data are mean ± SEM from 9 tumors for sham-transfected 
PANC-1 cells and for each of the 2 GAS clones.
Figure 4
GPC1 expression in tumor xenografts. (A) Immunoblotting. Tumors 
from sham-transfected and GAS PANC-1 cells (GAS6 and GAS7) 
were homogenized and incubated with control buffer, heparitinase, or 
heparitinase and chondroitinase ABC (Ch-ABC). Protein lysates were 
subjected to immunoblotting using affinity-purified rabbit anti-GPC1 
antibody as reported in Methods. Membranes from cell lysates were 
reprobed with an anti-ERK2 antibody to confirm equivalent loading 
of lanes. (B) Densitometric analysis. Frozen lysates for immunoblot-
ting from 6 sham, 5 GAS6, and 4 GAS7 tumors were subjected to 
densitometry. *P < 0.005 compared with sham.
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Effect of GPC1 levels on MAPK activation in the tumors. Inasmuch 
as many HBGFs frequently exert their mitogenic effects through 
activation of the MAPK pathway, it was of interest to determine 


































Effects of GPC1 levels on CD31 immunoreactivity in subcutaneous 
tumors. (A) Analysis of vessel number. Morphometric analysis of ves-
sel number was performed as described in Methods, using an anti-
CD31 antibody. Data are based on immunohistochemical staining of 
10 tumors from sham-transfected PANC-1 cells, 7 tumors from GAS6 
cells, and 10 tumors from GAS7 cells. (B) Analysis of vessel area. 
Morphometric analysis on the same tumors was carried out based 
on the area occupied by the vessels. Data are the means ± SEM. 
*P < 0.05 and **P < 0.01 compared with sham.
Figure 6
Effects of GPC1 levels on PCNA immunoreactivity in subcutaneous 
tumors. Morphometric analysis of PCNA immunoreactivity was per-
formed as described in Methods, using 10 tumors from sham-trans-
fected PANC-1 cells, 6 tumors from GAS6 cells, and 9 tumors from 
GAS7 cells. Data are means ± SEM. *P < 0.01 compared with sham.
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Effects of GPC1 levels on phospho-MAPK in subcutaneous tumors. 
(A) Immunoblotting for active ERK1/2. Lysates from 10 tumors from 
sham-transfected PANC-1 cells, 8 tumors from GAS6 cells, and 6 
tumors from GAS7 cells were subjected to immunoblotting with anti–
phospho-MAPK antibody as described in Methods. (B) Densitomet-
ric analysis. Band intensities for active ERK1 and active ERK2 were 
normalized to total ERK2 (loading control). Data are means ± SEM. 
*P < 0.05 compared with sham.
Figure 8
Effects of GPC1 levels on the expression of proangiogenic factors 
in PANC-1 cells in culture. RNA extracted from sham-transfected 
PANC-1 cells and GAS6 cells was subjected to real-time quantitative 
PCR. Relative expression levels were determined in triplicate. Data are 
means ± SEM from 3 different experiments. *P < 0.01 compared with 
the corresponding sham.
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Effects of GPC1 levels on the expression of proangiogenic factors 
in PANC-1–derived subcutaneous tumors. RNA extracted from 
tumors derived from sham-transfected PANC-1 cells and 2 GPC1 
antisense PANC-1 clones was subjected to real-time quantitative 
PCR. Relative expression levels were determined in triplicate. Data 
are the means ± SEM from 6 sham and 4 GAS6 and 3 GAS7 tumors. 
*P < 0.01 when compared with the corresponding sham.
Figure 10
Angiopoietin and Tie2 immunohistochemistry. Immunohistochemical 
staining for angiopoietin-1, angiopoietin-2, and Tie2 was performed 
as described in Methods. (A) Angiopoietin-1; (B) angiopoietin-2; (C) 
Tie2; (D) control staining in the absence of a primary antibody. Original 
magnification, ×100 (A and D); ×200 (B and C).
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Comparison of metastases in WT and GPC1-null mice. PANC-1 (A and 
B) and T3M4 (C and D) human pancreatic cancer cells were injected 
into the pancreas of WT (A and C) and GPC1-null (B and D) mice, as 
described in the legends to Table 2 (PANC-1) and Table 3 (T3M4). 
Metastatic lesions were visible in the mesentery of WT mice, but not 
in GPC1-null mice.
Table 1
Effects of suppressing cancer cell GPC1 on tumor metastasis
Parameter	 Sham	 GAS6	 GAS7
Primary tumor volume (mm3) 823 ± 89 567 ± 55A 492 ± 59B
Mice with lymph node metastasis 10 2C 1C
Total local lymph nodes 31 3 1
Total mesenteric region nodes 23 0 0
Mice with peritoneal  2 0 0 
 dissemination/ascites
Sham-transfected or GAS PANC-1 cells (2 × 106/site) were injected into 
the pancreas of nude mice, using 28-gauge needles. Six weeks later, 
the volumes of the intrapancreatic tumors and the extent of metastatic 
involvement were determined. Data are means ± SEM from 10 mice per 
group. AP < 0.03, BP < 0.01, and CP < 0.001 compared with control. Sta-
tistical analysis was not carried out with respect to local and mesenteric 
lymph node disease or peritoneal involvement.
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In vivo tumorigenicity assays and tissue preparation. To assess the effects of 
GPC1 suppression on tumorigenicity, 1 × 106 sham-transfected or GAS 
Table 2
Effects of host-derived GPC1 on PANC-1 metastasis
Mouse	 WT	 GPC1–/–
Mice with tumor 7/7 5/8
Tumor volume (mm3) 1,983 ± 307 1,113 ± 356A
Lymph node metastasis (no.) 319 0
Liver metastasis (no.) 4 0
Spleen metastasis (no.) 1 0
Microvessel density (% area) 5.8 ± 0.5 2.8 ± 0.5B
Sham-transfected PANC-1 cells (2 × 106/site) were injected into the 
pancreas of WT nude and GPC1-null nude mice, using 28-gauge 
needles. Ten weeks later, the volumes of the intrapancreatic tumors 
and the extent of metastatic involvement were determined. Tumor vol-
umes are means ± SEM of measurements from 7 WT mice (1 mouse 
in this group was found dead 2 weeks after cancer cell injection) and 5 
GPC1-null mice (3 mice in this group did not develop any grossly vis-
ible tumor during the 10-week period). Values for microvessel density 
were calculated as described in Methods. AP < 0.05 and BP < 0.0005 
compared with WT. Statistical analysis was not carried out with respect 
to lymph node involvement.
Figure 12
Effect of endogenous GPC1 levels on pulmonary metastasis of 
murine melanoma cells. Exponentially growing (1 × 105) murine 
B16-F10 melanoma cells were injected into the lateral vein of mice. 
Pulmonary metastases were counted 20–25 days later. Data are 
means ± SEM from 16 WT mice and 20 GPC1-null mice. *P < 0.006 
compared with WT.
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Effects of host-derived GPC1 on T3M4 metastasis
Mouse	 WT	 GPC1–/–
Mice with tumor 7/7 8/8
Tumor volume (mm3) 1,088 ± 289 1,115 ± 447
Lymph node metastasis (no.) 7 0
Liver metastasis (no.) 6 0
Spleen metastasis (no.) 7 0
Microvessel density (% area) 2.9 ± 0.6 1.4 ± 0.3A
T3M4 cells (2 × 105/site) were injected into the pancreas of WT nude 
and GPC1-null nude mice, using 28-gauge needles. Four weeks later, 
the volumes of the intrapancreatic tumors and the extent of metastatic 
involvement were determined. Tumor volumes are means ± SEM of 
measurements from 7 WT mice and 8 GPC1-null mice. Calculation of 
microvessel area was performed as described in Methods. AP < 0.04 
when compared with WT. Tumor volumes were similar in both groups 
of mice. Statistical analysis was not carried out with respect to lymph 
node involvement.
Figure 13
Effects of endogenous GPC1 levels on endothelial cell proliferation. 
Endothelial cells isolated from WT or GPC1-null mice were plated in 
triplicate on fibronectin-coated 96-well plates, serum-starved over-
night, and incubated for 48 h in the presence of 0.5% BSA (control) 
or 50 ng/ml VEGF-A. Data are means ± SEM. *P < 0.05 compared 
with control.
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Schematic representation of the role of 
GPC1 in tumor angiogenesis and metastasis. 
Endothelial cells expressing VEGF receptors, 
Tie2, and GPC1 (iv) are shown interacting with 
cancer cell–derived VEGF-A, angiopoietin-1, 
and angiopoietin-2 (i), cancer cell–derived 
GPC1 acting in trans (ii), shed GPC1 (iii), and 
fibroblast-derived GPC1 (v). Thus host- and 
tumor-derived GPC1 combine to contribute to 
tumor angiogenesis.
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